Ann Arbor, MINCT06679374Now EnrollingIRB Ready

Parkinson Disease Clinical Trial in Ann Arbor, MI

Access cutting-edge parkinson disease treatment through this phase 2 clinical trial at a research site in Ann Arbor. Study-provided care at no cost to qualified participants.

Sponsored by Vikas Kotagal

Quick Self-Assessment

See if you qualify for this Ann Arbor location

Preparing your pre-screening questions…

Expert Care in Ann Arbor

Access parkinson disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related parkinson disease treatment provided free

Apply for This Ann Arbor Location

Check if you qualify for this parkinson disease clinical trial in Ann Arbor, MI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Ann Arbor

    Convenient for MI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Ann Arbor site if eligible
  4. 4Begin participation

About This Parkinson Disease Study in Ann Arbor

This trial aims to test whether one year of Varenicline, when compared to placebo, can reduce fall risk and show improvement in the ability to multitask while walking. Participants that are eligible after screening for the study will be randomized to receive Varenicline or placebo. Along with the study medication participants will have visits (over the phone and in person), various tests and imaging, questionnaires, and laboratory collections.

Sponsor: Vikas Kotagal

Who Can Participate

Inclusion Criteria

Participants with a PD diagnosis based on the Movement Disorders Society Clinical Diagnostic Criteria for Parkinson's Disease at the time of baseline screening/enrollment visit
Participants with occipital association cortex cholinergic denervation in the lowest tertile of the normal range on F-fluoroethoxybenzovesamicol (FEOBV) Positron Emission Tomography (PET)
Participants with legally authorized representatives (LARs) able to co-sign documented informed consent or participants that have capacity to provide informed consent upon study enrollment as ascertained by the study-specific University of California, San Diego Brief Assessment of Capacity to Consent (UBACC)
Mild Cognitive Impairment consistent with Parkinson disease Mild Cognitive Impairment (PD-MCI)

Exclusion Criteria

Atypical Parkinsonian conditions other than Parkinson disease (PD)
Participants initially on certain dopamine blocking drugs (per protocol), specific anticholinergic drugs (trihexyphenidyl, benztropine), or specific cholinesterase inhibitor drugs (per protocol) at the in-person screening visit
Modified Hoehn and Yahr score of 4.0 or greater at the in-person screening visit
Current or previous (within last 6 months of in-person screening visit) use of any product or medication containing nicotinic agents, including use of tobacco products such as cigarettes, cigars, pipes, chewing tobacco, etc., e-cigarettes, over the counter (OTC) nicotine patches, chewing gum containing nicotine, or varenicline
Evidence of a stroke with both cortical and subcortical involvement or occipital lobe mass lesion on structural magnetic brain imaging (MRI) obtained at the in-person screening visit that would preclude co-registration and analysis of FEOBV PET data
Participants where magnetic resonance imaging (MRI) is contraindicated including, but not limited to, those with a pacemaker, presence of metallic fragments near the eyes or spinal cord, or cochlear implant
Severe claustrophobia precluding MRI or PET imaging
Participants limited by participation in research procedures involving ionizing radiation
Pregnancy (test within 48 hours of the PET imaging session in women of childbearing potential) or breastfeeding at the time of in-person screening visit
Participants with stage 4 or 5 chronic kidney disease at the time of in-person screening visit (estimated Creatinine Clearance \< 30 milliliters per minute)
Current, significant mood disorder at the time of in-person screening/enrollment visit defined as follows: persistent (lasting longer than 2 weeks) symptoms of depression or anxiety in the 30 days preceding informed consent, as determined by self-report
Evidence of active suicidal ideation as defined by an affirmative answer to either question 1 or 2 on the Columbia Suicide Severity Rating Scale (C-SSRS)
History of a myocardial infarction or unstable angina in the 90 days preceding enrollment visit
A current or previous history of epilepsy or any epileptic seizures in the 12 months preceding enrollment
Heavy alcohol use as defined by a score of 8 or greater on the Alcohol Use Disorders Identification Test (AUDIT-self-report version) at the time of screening/enrollment visit
Participants that are unable to swallow pills
Participants with a history of allergic reaction to varenicline
Participants that are actively taking part in another ongoing interventional (i.e., not observational) clinical trial

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Ann Arbor?

Yes, this clinical trial (NCT06679374) has an active research site in Ann Arbor, MI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Parkinson Disease Treatment Options in Ann Arbor, MI

If you're searching for parkinson disease treatment options in Ann Arbor, MI, this clinical trial (NCT06679374) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Ann Arbor research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced parkinson disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all parkinson disease clinical trials near you to find additional studies recruiting in your area.

More Parkinsons Disease Trials in Ann Arbor, MI

See all parkinsons disease clinical trials recruiting in Ann Arbor — not just this study.

Browse Parkinsons Disease Trials in Ann Arbor →

Browse More Trials by Condition

Parkinsons Disease TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Ann Arbor?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Ann Arbor, MI